BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8466849)

  • 1. Tumor cell proliferation and motility estimates are prognostic factors in malignant melanoma.
    Smolle J; Hofmann-Wellenhof R; Kofler R; Soyer HP; Kerl H
    Anal Cell Pathol; 1993 Mar; 5(2):113-24. PubMed ID: 8466849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of proliferation and motility in primary malignant melanoma of the skin.
    Smolle J; Hofmann-Wellenhof R; Kerl H
    J Cutan Pathol; 1992 Apr; 19(2):110-5. PubMed ID: 1597566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer simulation analysis of morphological patterns in human melanocytic skin tumours.
    Smolle J; Soyer HP; Smolle-Juettner FM; Stettner H; Kerl H
    Pathol Res Pract; 1991 Dec; 187(8):986-92. PubMed ID: 1792195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
    Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
    Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma.
    Barnhill RL; Katzen J; Spatz A; Fine J; Berwick M
    J Cutan Pathol; 2005 Apr; 32(4):268-73. PubMed ID: 15769275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
    Leiter U; Buettner PG; Eigentler TK; Garbe C
    J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
    Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
    Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
    Barnhill RL; Fine JA; Roush GC; Berwick M
    Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review.
    Vereecken P; Laporte M; Heenen M
    J Cutan Pathol; 2007 Feb; 34(2):139-45. PubMed ID: 17244025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
    Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
    Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of tumor cell motility and morphologic patterns. Part 1. Melanocytic skin tumors.
    Smolle J; Smolle-Juettner FM; Stettner H; Kerl H
    Am J Dermatopathol; 1992 Jun; 14(3):231-7. PubMed ID: 1510220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
    Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
    Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.
    Gimotty PA; Elder DE; Fraker DL; Botbyl J; Sellers K; Elenitsas R; Ming ME; Schuchter L; Spitz FR; Czerniecki BJ; Guerry D
    J Clin Oncol; 2007 Mar; 25(9):1129-34. PubMed ID: 17369575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.
    Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y
    Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant melanoma in Turkey: a single institution's experience on 475 cases.
    Tas F; Kurul S; Camlica H; Topuz E
    Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
    Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D
    J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotic rate in melanoma: a reexamination.
    Attis MG; Vollmer RT
    Am J Clin Pathol; 2007 Mar; 127(3):380-4. PubMed ID: 17276944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival.
    Döme B; Somlai B; Tímár J
    Anticancer Res; 2000; 20(5C):3971-4. PubMed ID: 11268486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors in thin cutaneous malignant melanoma].
    Massi D; Franchi A; Santucci M
    Pathologica; 2002 Dec; 94(6):282-9. PubMed ID: 12540991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of melanocytic lesions: new, controversial, and clinically important issues.
    Scolyer RA; Thompson JF; Stretch JR; Sharma R; McCarthy SW
    J Surg Oncol; 2004 Jul; 86(4):200-11. PubMed ID: 15221927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.